Status:
UNKNOWN
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Pharmacologic alternatives in statin-intolerant patients include ezetimibe and nutraceuticals (i.e. compounds derived from foods with cholesterol lowering actions). The investigators will compare the ...
Detailed Description
Background Treatment with statins has a class I indication after percutaneous coronary intervention (PCI), but is often discontinued by patients due to side effects. Pharmacologic alternatives shown...
Eligibility Criteria
Inclusion
- Angiographically-proven coronary artery disease
- Recent (\< 12 months) percutaneous coronary intervention
- Class I indication to receive statin treatment
- Previous (\< 12 months) withdrawn of a statin due to side effects
- Unwilling to receive treatment with an alternative statin
- Able to understand and willing to sign the informed consent form
Exclusion
- • Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01490229
Start Date
January 1 2013
End Date
December 1 2016
Last Update
March 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Raffaele Pisana
Rome, Italy, 00100